Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy

Abstract

The patient had complete response to the combination of paclitaxel/platinum in the first line. Subseguent four recurrences also showed a complete response to this combination.

The chronic toxicity, including hypersensitivity and nephrotoxicity could be controlled by modifying the regimen.In conclusion, recurrent EOC in BRCA1 mutation carriers may retain sensitivity to paclitaxel/platinum combination chemotherapy.